Boston Scientific Co. (NYSE:BSX) Stake Lessened by Advisory Alpha LLC

Advisory Alpha LLC lessened its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 55.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 2,405 shares of the medical equipment provider's stock after selling 3,042 shares during the quarter. Advisory Alpha LLC's holdings in Boston Scientific were worth $243,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in BSX. TFC Financial Management Inc. increased its holdings in Boston Scientific by 308.8% during the 4th quarter. TFC Financial Management Inc. now owns 278 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 210 shares in the last quarter. Colonial Trust Co SC increased its holdings in Boston Scientific by 1,625.0% during the 4th quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after acquiring an additional 260 shares in the last quarter. Investment Management Corp VA ADV purchased a new position in Boston Scientific during the 4th quarter valued at about $25,000. Sunbeam Capital Management LLC purchased a new position in Boston Scientific during the 4th quarter valued at about $26,000. Finally, Ameriflex Group Inc. acquired a new stake in shares of Boston Scientific during the 4th quarter worth about $31,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

Several research firms have issued reports on BSX. Argus set a $130.00 price target on shares of Boston Scientific in a research note on Tuesday, February 18th. Barclays raised their price target on shares of Boston Scientific from $118.00 to $125.00 and gave the stock an "overweight" rating in a research note on Friday, April 25th. Evercore ISI raised their price target on shares of Boston Scientific from $110.00 to $112.00 and gave the stock an "outperform" rating in a research note on Thursday, April 24th. Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a research note on Thursday, May 8th. Finally, Raymond James raised their price target on shares of Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research note on Thursday, February 6th. Twenty-one investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of "Buy" and an average target price of $116.00.

Insider Buying and Selling at Boston Scientific

In other news, SVP Vance R. Brown sold 4,826 shares of Boston Scientific stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $95.09, for a total transaction of $458,904.34. Following the sale, the senior vice president now owns 36,193 shares in the company, valued at $3,441,592.37. This trade represents a 11.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 4,572 shares of Boston Scientific stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $104.54, for a total transaction of $477,956.88. Following the sale, the executive vice president now owns 18,705 shares in the company, valued at $1,955,420.70. This represents a 19.64% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 411,970 shares of company stock valued at $42,406,693 over the last ninety days. Corporate insiders own 0.50% of the company's stock.

Boston Scientific Trading Up 0.2%

BSX stock traded up $0.24 during midday trading on Thursday, reaching $102.67. 8,242,498 shares of the company's stock traded hands, compared to its average volume of 6,454,802. The company has a market capitalization of $151.90 billion, a P/E ratio of 82.14, a PEG ratio of 2.79 and a beta of 0.68. The company has a debt-to-equity ratio of 0.41, a current ratio of 1.08 and a quick ratio of 1.02. Boston Scientific Co. has a fifty-two week low of $71.88 and a fifty-two week high of $107.17. The business has a 50-day moving average price of $100.47 and a two-hundred day moving average price of $98.29.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.08. The firm had revenue of $4.66 billion for the quarter, compared to analysts' expectations of $4.57 billion. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Boston Scientific's revenue was up 20.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.56 earnings per share. Equities research analysts forecast that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.